One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical TrialsA Meta-analysis
Irbaz Bin Riaz, MBBS, MS1,2,3; Mahnoor Islam, MBBS4; Waleed Ikram, MBBS3; Syed Arsalan Ahmed Naqvi, MBBS3; Hamza Maqsood, MBBS5; Yusra Saleem, MBBS4; Anum Riaz, MBBS6; Praful Ravi, MB, BChir2; Zhen Wang, PhD7; Syed A. Hussain, MBBS, MSc, MD8; Jeremy Lyle Warner, MD, MS9; Folakemi T. Odedina, PhD10; Narjust Duma, MD2; Parminder Singh, MD3; Kenneth L. Kehl, MD, MPH2; Sophia C. Kamran, MD1; Mohammad Hassan Murad, MD7; Adam Landman, MD1; Eliezer Van Allen, MD2; Alan Haruo Bryce, MD3
doi : 10.1001/jamaoncol.2022.5511
February 2023, Vol 9, No. 2, Pages 158-288
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With CancerA National COVID Cancer Cross-sectional Evaluation
Lennard Y. W. Lee, DPhil; Michael Tilby, MBChB; Thomas Starkey, MSci; et al.
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U. Lin, MD1; Rashmi K. Murthy, MD, MBE2; Vandana Abramson, MD3; Carey Anders, MD4; Thomas Bachelot, MD, PhD5; Philippe L. Bedard, MD6; Virginia Borges, MMSc, MD7; David Cameron, MD, MA8; Lisa A. Carey, MD9; A. Jo Chien, MD10; Giuseppe Curigliano, MD, PhD11,12; Michael P. DiGiovanna, MD, PhD13; Karen Gelmon, MD14; Gabriel Hortobagyi, MD2; Sara A. Hurvitz, MD15; Ian Krop, MD, PhD1,13; Sherene Loi, MD, PhD16; Sibylle Loibl, MD, PhD17; Volkmar Mueller, MD18; Mafalda Oliveira, MD, PhD19; Elisavet Paplomata, MD20,21; Mark Pegram, MD22; Dennis Slamon, MD15; Amelia Zelnak, MD, MSc23; Jorge Ramos, DO24; Wentao Feng, PhD24; Eric Winer, MD1,13
Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment
Yuhua Bao, PhD1,2; Hao Zhang, PhD1; Eduardo Bruera, MD3; Russell Portenoy, MD4,5,6; William E. Rosa, PhD, MBE, APRN7; M. Carrington Reid, MD, PhD8; Hefei Wen, PhD9
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell CarcinomaA Meta-analysis Including Low PD-L1 Subgroups
Dominic Wei Ting Yap1; Alberto Giovanni Leone, MD2; Nicky Zhun Hong Wong1; Joseph J. Zhao, MBBS1; Jeremy Chee Seong Tey, MBBS, FRANZCR, MPH1,3; Raghav Sundar, MBBS, PhD1,4,5,6,7; Filippo Pietrantonio, MD2
External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups
Stefan Timmerman, MD1,2; Lil Valentin, MD, PhD3,4; Jolien Ceusters, MSc5; Antonia C. Testa, MD, PhD6; Chiara Landolfo, MD, PhD7; Povilas Sladkevicius, MD, PhD3,4; Caroline Van Holsbeke, MD, PhD8; Ekaterini Domali, MD, PhD9; Robert Fruscio, MD, PhD10; Elisabeth Epstein, MD, PhD11; Dorella Franchi, MD, PhD12; Marek J. Kudla, MD, PhD13; Valentina Chiappa, MD, PhD14; Juan L. Alcazar, MD, PhD15; Francesco P. G. Leone, MD, PhD16; Francesca Buonomo, MD, PhD17; Maria Elisabetta Coccia, MD, PhD18; Stefano Guerriero, MD, PhD19; Nandita Deo, MD20; Ligita Jokubkiene, MD, PhD3,4; Jeroen Kaijser, MD, PhD21; Giovanni Scambia, MD, PhD6; Rochelle Andreotti, MD22,23; Dirk Timmerman, MD, PhD1,2; Tom Bourne, MD, PhD1,7; Ben Van Calster, PhD1,24; Wouter Froyman, MD, PhD1,2
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use
Emese Zsiros, MD, PhD1; Jason Ricciuti, MD1,2; Steven Gallo, MS3; Deanna Argentieri, PharmD4; Kristopher Attwood, PhD5; Wenyan Ji, MA6; Alan Hutson, PhD5; Paul Visco, MA3; Devon Coffey, MS7; Grazyna Riebandt, PharmD4; Jaron Mark, MD8; Aaron Varghese, MD1; Suzanne M. Hess, PhD1; Thomas Furlani, PhD3; Andrew Fabiano, MD9; Mark Hennon, MD10; Sai Yendamuri, MD10; Eric C. Kauffman, MD11; Kimberly E. Wooten, MD12; Wesley L. Hicks Jr, MD12; Jessica Young, MD13; Kazuaki Takabe, MD, PhD13; Kunle Odunsi, MD, PhD14; Amy A. Case, MD15; Brahm H. Segal, MD16; Candace S. Johnson, PhD17; Boris Kuvshinoff II, MBA, MD13; Steven Nurkin, MD13; Gyorgy Paragh, MD, PhD18; Oscar de Leon-Casasola, MD19
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk NeuroblastomaA Phase 2 Randomized Clinical Trial
Irene Y. Cheung, ScD1; Audrey Mauguen, PhD2; Shakeel Modak, MD1; Govind Ragupathi, PhD3; Ellen M. Basu, MD, PhD1; Stephen S. Roberts, MD1; Brian H. Kushner, MD1; Nai-Kong Cheung, MD, PhD1
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected MelanomaA Secondary Analysis of the SWOG S1404 Randomized Clinical Trial
Joseph M. Unger, PhD1; Amy Darke, MS1; Megan Othus, PhD1; Thach-Giao Truong, MD2; Nikhil Khushalani, MD3; Kari Kendra, MD, PhD4; Karl D. Lewis, MD5; Bryan Faller, MD6; Pauline Funchain, MD7; Elizabeth I. Buchbinder, MD8; Ahmad A. Tarhini, MD, PhD3; John M. Kirkwood, MD9; Elad Sharon, MD10; Vernon Sondak, MD3; Samantha R. Guild, JD11; Kenneth Grossmann, MD, PhD12; Antoni Ribas, MD, PhD13; Sapna P. Patel, MD14
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non–Small Cell Lung Cancer
Kirsty W. C. Lee, MBChB1; Molly S. C. Li, MBBS1,2; Wanxia Gai, PhD3; Yat Ming Lau, MBBS4; Allen K. C. Chan, PhD3; Oscar S. H. Chan, MBChB5; Chee Khoon Lee, PhD6; Rebecca M. W. Yeung, MBBS5; Sherwood Y. H. Fung, PhD3; Wai F. Cheung, MPhil3; Vivian W. Chan, BSc1; Linda Leung, MPH4; Kenny N. P. Kam, MBChB4; Tony S. K. Mok, MD1,2
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, MD1; Shaily Arora, PharmD1; Laleh Amiri-Kordestani, MD1; R. Angelo de Claro, MD1; Lola Fashoyin-Aje, MD, MPH1; Nicole Gormley, MD1; Tamy Kim, PharmD2; Steven Lemery, MD, MHS1; Gautam U. Mehta, MD1; Emma C. Scott, PhD1; Harpreet Singh, MD1; Shenghui Tang, PhD1; Marc R. Theoret, MD1,2; Richard Pazdur, MD1,2; Paul G. Kluetz, MD1,2; Julia A. Beaver, MD1,2
doi : 10.1001/jamaoncol.2022.5985
Single-arm trials have allowed for transformative therapies to be made available to patients expeditiously. However, using single-arm trials to support drug approval presents several challenges that must be carefully considered.
An Atypical Rash on the Chest
Tarneem Darwish, MD1; Phillip Bomeisl, MD1; Ankit Mangla, MD2
Prescription Drug Provisions in the Inflation Reduction ActAny Relief of Financial Hardship for Patients With Cancer?
Ya-Chen Tina Shih, PhD1; K. Robin Yabroff, PhD2; Cathy J. Bradley, PhD, MPA3
Clinical Trials and Digital Pathology—Toward Quantitative Therapeutic Immunohistochemistry and Tissue Hybridization
Manuel Salto-Tellez, MD1; Jorge S. Reis-Filho, MD, PhD2
Public Access to Scientific Research Findings and Principles of Biomedical Research—A New Policy for the JAMA Network
Kirsten Bibbins-Domingo, PhD, MD, MAS1; Brian Shields, MBA2; John Z. Ayanian, MD, MPP3,4; Robert O. Bonow, MD, MS5,6; Neil M. Bressler, MD7,8; Dimitri Christakis, MD, MPH9,10; Mary L. Disis, MD11,12; S. Andrew Josephson, MD13,14; Melina R. Kibbe, MD15,16; Dost Öngür, MD, PhD17,18; Jay F. Piccirillo, MD19,20; Rita F. Redberg, MD, MPH21,22; Frederick P. Rivara, MD, MPH23,24; Kanade Shinkai, MD, PhD25,26; Thomas J. Easley27
COP27 Climate Change Conference—Urgent Action Needed for Africa and the World
Lukoye Atwoli1; Gregory E. Erhabor2; Aiah A. Gbakima3; Abraham Haileamlak4; Jean-Marie Kayembe Ntumba5; James Kigera6; Laurie Laybourn-Langton7; Bob Mash8; Joy Muhia9; Fhumulani Mavis Mulaudzi10; David Ofori-Adjei11; Friday Okonofua12; Arash Rashidian13; Maha El-Adawy14; Siaka Sidibé15; Abdelmadjid Snouber16; James Tumwine17; Mohammad Sahar Yassien18; Paul Yonga19; Lilia Zakhama20; Chris Zielinski21
Declining Representation and Reporting of Racial and Ethnic Minority Patients in Prostate Cancer Clinical Trials Despite Persistent Health Disparities—Where Progress Confronts Limitations
Curtiland Deville Jr, MD1; Hala T. Borno, MD2,3
Variability in COVID-19 Vaccine Response Among People With CancerWhat Health Care Strategy Best Protects the Vulnerable?
Michael Hoerger, PhD, MSCR, MBA1,2,3,4; James Gerhart, PhD5; Maria C. Swartz, PhD, MPH, RD, LD6
The Multidisciplinary Cancer Conference
Eric K. Singhi, MD1; Jill Feldman2; Howard (Jack) West, MD3
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
Aaron J. Grossberg, MD, PhD1; Krishan R. Jethwa, MD2; Susannah G. Ellsworth, MD3
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
William A. Hall, MD1,2; Douglas B. Evans, MD2; Susan Tsai, MD, MHS2
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
Neris Dincer, MD1; Gamze Ugurluer, MD1; Enis Ozyar, MD1
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
Brace Hintz, MD1; Vincent J. Lee, MD1
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply
Matthew H. G. Katz, MD1; Joseph M. Herman, MD2; Eileen M. O’Reilly, MD3
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters
Liang Wang, MD1
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters—Reply
Xinhua Wang, MD1; Ken H. Young, MD2; Mingzhi Zhang, MD1
Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer
Xinmu Zhang, MD, PhD1; Cong Ning, MD, PhD1; Haitao Zhao, MD1
Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer—Reply
Harry H. Yoon, MD, MHS1; Qian Shi, PhD2; Jaffer A. Ajani, MD3
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes
Yin Zhang, MD, MPH1; Edward L. Giovannucci, MD, ScD1,2
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes
Rachel G. Miller, PhD1; Tina Costacou, PhD1
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes
Haydee Verduzco-Aguirre, MD1; Maria Eugenia Penados-Ovalle, MD2; Leonardo Guadalupe Mancillas-Adame, MD3
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes—Reply
Yuanjie Mao, MD, PhD1,2; Wenjun Zhong, PhD3
